Originator and Biosimilar Biologics: For Patients and Healthcare Providers

Biosimilars: Myths Versus Evidence

Biologic medicines—from insulin to cancer therapies—have transformed healthcare, but they're expensive. Biosimilars offer cost-effective alternatives once the originator patent expires, yet misconceptions abound: Are biosimilars actually equivalent? Will they work the same? This course builds the clinical and scientific evidence to answer these questions clearly.

Understand what makes a biosimilar and how regulators ensure it's safe and effective. See case studies across oncology, rheumatology, gastrointestinal disease, and others. Learn how biosimilars expand access and lower costs without sacrificing outcomes. For clinicians, patients, and healthcare administrators, this course dismantles myths and clarifies the practical impact of biosimilar adoption on care delivery and patient economics.